Pralsetinib 100 mg Oral Capsule
RxNorm 2394941
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2394941 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: pralsetinib 100 mg Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Pralsetinib 100 mg Oral Capsule
(Atom ID: 12433525)
PSNPrescribable
Prescribable Name (PSN):
Pralsetinib 100 mg Oral Capsule
(Atom ID: 12433534)
PTPrescribable
Designated preferred name (PT):
Pralsetinib 100 mg oral capsule
(Atom ID: 12537245)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely pralsetinib 100 mg/1 each conventional release oral capsule (clinical drug)
(Atom ID: 12537685)
Patient Education
Pralsetinib
Pralsetinib is used to treat a certain type of non small-cell lung cancer (NSCLC) in adults that has spread to other parts of the body. It is also used to treat a certain type of thyroid cancer in adults and children 12 years of age and older that is getting worse or that has spread to other parts of the body. Pralsetinib is used to treat a certain type of thyroid cancer in adults and children 12 years of age and older that is getting worse or that has spread to other parts of the body and cannot be treated with radioactive iodine. Pralsetinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.
[Learn More]
* Please review the disclaimer below.